Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview

[SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology Consensus approach Clinical Neurology 610 tau Proteins cerebrospinal fluid [Amyloid beta-Peptides] DIAGNOSIS RECOMMENDATIONS Cerebrospinal fluid biomarkers Alzheimer Disease 616 CRITERIA Humans ddc:610 cerebrospinal fluid [Peptide Fragments] clinical report cerebrospinal fluid biomarkers consensus approach Science & Technology Amyloid beta-Peptides Featured Articles 9. Industry and infrastructure diagnosis [Alzheimer Disease] Radboudumc 3: Disorders of movement DCMN: Donders Center for Medical Neuroscience Alzheimer's disease 16. Peace & justice Clinical report Peptide Fragments 3. Good health cerebrospinal fluid [Alzheimer Disease] Alzheimer's disease; cerebrospinal fluid biomarkers; clinical report; consensus approach; harmonization cerebrospinal fluid [Biomarkers] cerebrospinal fluid [tau Proteins] Harmonization harmonization Neurosciences & Neurology Human medicine Life Sciences & Biomedicine Alzheimer’s disease Biomarkers
DOI: 10.1002/alz.12545 Publication Date: 2021-12-22T12:18:10Z
ABSTRACT
Abstract Introduction The current practice of quantifying cerebrospinal fluid (CSF) biomarkers as an aid in the diagnosis Alzheimer's disease (AD) varies from center to center. For a same biochemical profile, interpretation and reporting results may differ, which can lead misunderstandings raises questions about commutability tests. Methods We obtained description (pre‐)analytical protocols sample reports 40 centers worldwide. A consensus approach allowed us propose harmonized comments corresponding different CSF biomarker profiles observed patients. Results procedures were similar between centers. There was considerable heterogeneity cutoff definitions report comments. therefore identified selected by most accurate informative regarding context AD diagnosis. Discussion This is first time that are proposed across worldwide specialized laboratories involved AD.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (30)
CITATIONS (37)